The Catalyst

Most Recent Posts


Later today, PhRMA President & CEO John Castellani will be participating in Research!America's annual National Health Research Forum: World Class to 2nd Class -- Confronting the Risks to U.S. Science and Innovation.

03.12.12 | By Kate Connors

Writer Carl Zimmer had a thought-provoking book review in The Wall Street Journal over the weekend.


Take a look at the thoughts of Dr. Michael Hodin, a senior fellow at the Council on Foreign Relations writing in the Fiscal Times. His piece looks at how technological and medical innovation is needed to meet requirements of an aging population. He writes:


There are some more warning signs today of the incredible cost of dementia to both patients and our economy.

03.07.12 | By Preet Bilinski

We continue the conversation of rare diseases as a global health challenge with Lundbeck's Dr. Christopher Silber. Offering effective therapies is a fundamental component of the commitment to help improve the lives of people with challenging, unmet medical needs. At Lundbeck the focus is on making a difference for patients, no matter how complex the condition.

What compelled you to join the fight against rare diseases?


Washington, D.C. (March 6, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matt Bennett issued the following statement:

“AARP has released yet another misleading pricing report that ignores key facts about the marketplace for prescription medicines and paints an inaccurate picture of prescription drug spending in the U.S.


It's a startling moment, when what seems like a distant problem hits close to home. In a one-stoplight town in Eastern Kentucky, my neighbor's alarming descriptions of prescription drug abuse were as distantly vague to me as someone attempting to explain what New York City felt like; it just didn't compute. Up until I encountered it firsthand, I'd heard gossip about locals getting addicted to pain pills but it seemed like an apparition, something blown out of proportion in a hairdresser's hyperbole.

03.05.12 | By Preet Bilinski

As a pretty healthy person, the only time I really struggle to breathe is after a long grueling run. But for individuals with asthma it can be a common occurrence. Today, more than 24 million American adults and children suffer from asthma, with that number continuing to grow, according to the CDC. Asthma is a narrowing of the airways to the lungs caused by inflammation in the air passages, resulting from both genetic and environmental influences. Symptoms can include difficulty breathing, wheezing, and coughing tightness in the chest.

03.02.12 | By Preet Bilinski

Today, we have a guest post from Eileen Cannon, Executive Director for the PhRMA Foundation. Below, Eileen discusses the challenges and the progress made by the PhRMA Foundation fellows in regard to rare disease research.

03.02.12 | By Greg Lopes

We have always espoused the view that good adherence to prescription medicines can improve health outcomes, help control health care costs, and improve patients' lives. Here at PhRMA, we pay close attention to the literature that supports this belief.

03.01.12 | By Kate Connors

It's no secret that encouraging adherence among patients can be a challenge. We know that patients who are more compliant regarding their prescribed treatment regimen tend to have better health outcomes. However, the problem has been finding a way to effectively encourage compliance.

02.29.12 | By Preet Bilinski

Although we are recognizing today as Rare Disease Day, for some people, every day is rare disease day. Ask Sigma-Tau what's the difference between their commitment to fighting a disease affecting 300 and 3,000,000, and they'll tell you: nothing. Below, we sat down with Sigma-Tau's Gregg Lapointe to discuss this important issue:

02.29.12 | By John Castellani

Today is international Rare Disease Day, an event established to support the millions of people around the world affected by rare diseases. This year's focus is on solidarity and the need for collaboration in the field.

02.28.12 | By Jack Cox

Today, we have a guest post from Jack Cox, Senior Director of Media Relations for Sanofi US. Below, Jack discusses how the times are changing with regard to how pharmaceutical companies communicate online.


There were a couple of recent posts on vaccines and vaccination worth a look. One focuses on the future and the prospects for the development of a "universal" vaccine to control the flu and reduce the potential for pandemics. The second points out that unvaccinated children still pose a potential threat to vaccinated children.